Browsing Tag
NEREUS
3 posts
Vanda Pharmaceuticals VQW-765 fails Phase 3 anxiety trial as stock faces fresh pressure
Vanda Pharmaceuticals has paused development of VQW-765 after a 546-patient Phase 3 study failed to demonstrate a significant reduction in social anxiety symptoms. The setback removes a near-term clinical catalyst, placing greater importance on its commercial product launches, cash position and remaining regulatory milestones.
Vanda Pharmaceuticals (VNDA) bets on GLP-1 adherence gap with new Nereus vomiting-prevention study
Vanda Pharmaceuticals has launched the Thetis study to test Nereus in GLP-1-related vomiting. Read what this means for obesity drug adherence and VNDA.
Vanda Pharmaceuticals (NASDAQ: VNDA) wins long-awaited FDA approval for NEREUS, first new motion sickness drug in 40+ years
Find out how Vanda Pharmaceuticals’ FDA-approved NEREUS (tradipitant) is redefining motion sickness treatment after 40 years of stagnation. Read the full story now.